Awaiting development: Guidance and quality standards
Showing 1 to 4 of 4
| Title | Type |
|---|---|
| Deucravacitinib for treating active psoriatic arthritis [TSID11981] | Technology appraisal guidance |
| Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208] | Technology appraisal guidance |
| Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590] | Technology appraisal guidance |
| Tildrakizumab for treating active psoriatic arthritis [TSID12218] | Technology appraisal guidance |